On February 18, 2026, FDA leadership signaled a major shift in how effectiveness is demonstrated for most drugs: the default expectation will be one adequate and well-controlled pivotal study, paired with confirmatory evidence, rather than the long-standing “two confirmatory trials” norm.

FDA Commissioner Marty Makary and Vinay Prasad described the change in a New England Journal of Medicine perspective, arguing that the number of trials is not, by itself, a safeguard. Study quality, design rigor, endpoints, controls, and statistics are what determine whether conclusions are valid.

This announcement has sparked immediate debate. Former FDA officials and industry voices have raised concerns about transparency, implementation details, and predictability, including the absence (so far) of the usual “how we’ll do this” scaffolding that typically accompanies a shift of this magnitude.

So what does this mean for companies building submissions and for quality teams supporting them? It means the quality system around evidence matters more than ever.

The Change

FDA’s message isn’t “less evidence.” It’s closer to:
“One pivotal trial can be enough if the program is engineered to withstand scrutiny.”

This concept is not entirely new in the FDA ecosystem. FDA has already issued guidance framing how one adequate and well-controlled investigation plus confirmatory evidence may support “substantial evidence” in appropriate circumstances.

Also important: the regulatory foundation has long emphasized “adequate and well-controlled studies” and how they’re designed, not simply counting trials.

The practical takeaway: if your pivotal study is the one that “carries” the program, your margin for error shrinks.

What Makes This a Quality Topic

When the default becomes “one pivotal,” the organization’s ability to prevent avoidable failure shifts heavily onto:

1) Protocol quality and change control

Any appearance of endpoint drift, post-hoc statistical reshaping, or inconsistent data handling becomes more consequential because you don’t have a second pivotal trial to “average out” program noise.

2) Data integrity and traceability

Confirmatory evidence only helps if it’s credible, reproducible, and traceable, with clear lineage from source to analysis to decision.

3) Vendor/supplier quality oversight

CROs, central labs, eCOA/ePRO platforms, imaging vendors, and data processors become part of your “evidence supply chain.” A weak link here is not a vendor issue, it becomes a submission risk.

4) Postmarket readiness as part of the evidence story

Even supporters of the shift are calling out that postmarket surveillance expectations will matter, but details are still emerging.
That means companies should assume FDA will expect stronger real-world monitoring capability, earlier.

The “One Pivotal Trial Readiness” Checklist

If your program is aligning to this model, consider a focused readiness sprint:

A. Pivotal trial defensibility

• Controls and comparators: Are they appropriate, current, and clinically credible?
• Endpoints: Are they meaningful or heavily surrogate-driven?
• Effect size and powering: Do assumptions hold up under conservative review?

B. Confirmatory evidence plan (defined early, not retrofitted)

• What is confirmatory (RWE, external controls, biomarkers, supportive studies)?
• What makes it reliable (governance, data provenance, statistical pre-specification)?
• How will you demonstrate consistency across sources?

C. Quality controls across the evidence lifecycle

• Protocol deviation trending and CAPA triggers
• Audit trails for data transformations and vendor outputs
• Statistical analysis plan governance (including “who can change what, when”)
• Vendor qualification + oversight plan tied to critical-to-quality data elements

D. Postmarket and signal management

• Safety signal detection process maturity
• Complaints, AE reporting, and benefit-risk updates integrated into a single story
• Monitoring plan that can “stand up” to increased scrutiny if approvals come faster

What To Watch Next

Multiple expert reactions have pointed to the same gap: the need for implementation clarity – the “when FDA will flex,” “what confirmatory evidence must look like,” and “how consistency will be evaluated.”

Until FDA provides more formal direction, the safest assumption for sponsors is:

The bar doesn’t drop. The bar shifts from quantity of trials to quality of the evidence system.

How QSN helps

QSN can support sponsors and quality teams by:

• Building an evidence-quality operating model (governance, traceability, controls)
• Auditing trial/vendor quality systems for submission-critical risks
• Designing confirmatory evidence governance (RWE/data provenance + decision logs)
• Integrating postmarket readiness into premarket strategy so the story is coherent end-to-end

If your organization is considering a “one pivotal + confirmatory” approach, we can help you pressure-test the program before you learn the hard way during review.